On January 6, 2016, Cortexyme, Inc. closed the transaction. The company received $7,081,358 in its second tranche and received $15,000,000 in the transaction till now. The series A round was led by new investor Pfizer Inc. and also included participation from new investor Takeda Ventures, Inc., existing investor Dolby Family Ventures, and other private investors.

As part of the round, Margi McLoughlin, Executive Director, Worldwide Business Development for Pfizer Inc., Ilan Zipkin, Senior Investment Director at Takeda Ventures, Inc., and David Lamond, President of Lamond Capital will join the company's board of directors.